Kodiak Sciences Inc. (KOD) Stock Price & Analysis
Kodiak Sciences Inc. (KOD) rose 4.90% to USD 31.06 as of June 10, 2026 at 00:46 UTC, according to Nexqual real-time market data.
KOD last closed at USD 29.61; the session ranged USD 29.21–31.12 on volume of 689,082 shares. Market capitalization is $1.94B, with a 52-week range of USD 3.43–47.84 (NGM). Source: Nexqual, June 10, 2026 at 00:46 UTC.
Key Statistics (as of June 10, 2026 at 00:46 UTC)
| Price | USD 31.06 |
|---|---|
| Change | ▲ 4.90% (up) |
| Previous Close | USD 29.61 |
| Open | USD 30.09 |
| Day Range | USD 29.21 – 31.12 |
| 52-Week Range | USD 3.43 – 47.84 |
| Volume | 689,082 shares |
| Market Cap | $1.94B |
| Exchange | NGM |
Technical Analysis (KOD)
Nexqual's technical model rates KOD "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:46 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 32.35 (neutral) |
| vs SMA50 | Below (USD 39.79) |
| MACD | -2.2 (negative) |
Analyst Ratings (KOD)
Wall Street analysts rate KOD "None" based on 6 analysts, with a mean price target of USD 62.67 (range USD 56–80), per Nexqual as of June 10, 2026 at 00:46 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 62.67 |
| High Target | USD 80 |
| Low Target | USD 56 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (KOD)
| Next Earnings Date | 2026-05-07 |
|---|---|
| EPS Estimate | USD -0.96 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.94 vs est -1.01 ▲ beat |
| 2025-12-31 | USD -1.04 vs est -1.05 ▲ beat |
| 2025-09-30 | USD -1.16 vs est -1.04 ▼ miss |
| 2025-06-30 | USD -1.03 vs est -1.05 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
Financials & Fundamentals (KOD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -208.80% |
| Debt / Equity | 49.95 |
| Current Ratio | 3.54 |
| Total Cash | $169.53M |
| Total Debt | $55.99M |
| Free Cash Flow | $-52.15M |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
Financial Health Score (KOD)
Nexqual rates Kodiak Sciences Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:46 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $170M cash vs $56M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$147M |
| Efficiency | Critical — ROE -209%, ROA -49.1% |
Ownership (KOD)
| Insider Ownership | +5.18% |
|---|---|
| Institutional Ownership | +99.56% |
| Shares Outstanding | 62.58M |
| Float | 39.28M |
| Short % of Float | +25.87% |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
Leadership (KOD)
Kodiak Sciences Inc. is led by Victor Perlroth (age 51), Co-Founder, Chairman, CEO & President, per Nexqual as of June 10, 2026 at 00:46 UTC.
| Co-Founder, Chairman, CEO & President | Victor Perlroth (age 51) |
|---|---|
| Executive VP, CFO & Secretary | John A. Borgeson (age 62) |
| Chief Technology Officer | Wayne To M.Phil. |
| Chief Scientific Officer | Dolly S. Chang M.D., M.P.H. |
| Senior Vice President of Development | Hong Liang (age 53) |
Major Backers & Investors (KOD)
Notable institutional backers of Kodiak Sciences Inc. include Baker Bros. Advisors, LP, Price (T.Rowe) Associates Inc, Braidwell LP , according to Nexqual as of June 10, 2026 at 00:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 31.83% |
| Price (T.Rowe) Associates Inc | 3.26% |
| Braidwell LP | 2.91% |
| Goldman Sachs | 2.7% |
| RTW Investments LP | 2.38% |
| TCG Crossover Management, LLC | 2.31% |
| Boxer Capital Management, LLC | 2.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.91% |
| State Street | 6% |
| Vanguard Group | 5.42% |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
From Kodiak Sciences Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- We are advancing our platform technology to embed small molecules and other active pharmaceutical ingredients ("API") into our proprietary biopolymer backbone to enable high drug-antibody-ratio ("DAR") medicines.
- Beyond its clinical pipeline, Kodiak is advancing its platform technology to embed small molecules and other active pharmaceutical ingredients ("API"), into Kodiak's proprietary biopolymer backbone to enable high drug-antibody ratio ("DAR") medicines.
- Vabysmo demonstrated non-inferior visual acuity outcomes versus Eylea in Phase 3 trials across wet AMD, DME and RVO, with extended dosing intervals of up to every 16 weeks in a meaningful proportion of patients. 6   Regeneron's Eylea HD is a major competitive product, with FDA approvals across wet AMD, DME, DR and RVO.
- Drug Development In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations, and biologics under the FDCA, the Public Health Service Act, or PHSA, and their implementing regulations.
Partnerships
- In addition to advancing our pipeline, we have made progress in process development and commercial scale manufacturing, including the commissioning and regulatory approval of Ursus, our dedicated commercial-scale drug substance manufacturing facility that was custom-designed and built in collaboration with Lonza, a leading drug contract manufacturing firm.
- Antibody Biopolymer Conjugate Drug Substance Manufacturing In August 2020, we entered into a manufacturing agreement with Lonza for the clinical and commercial supply of the Company's antibody biopolymer conjugate drug substance which included a custom-built manufacturing facility.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBIO | BridgeBio Pharma, Inc. | USD 67.68 | ▲ 0.1% |
| STOK | Stoke Therapeutics, Inc. | USD 29.37 | ▼ 2.13% |
| PTGX | Protagonist Therapeutics, Inc. | USD 105.87 | ▲ 8.72% |
| KNSA | Kiniksa Pharmaceuticals Interna | USD 48.7 | ▲ 0.58% |
| DNLI | Denali Therapeutics Inc. | USD 20.79 | ▲ 6.51% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:46 UTC. This page is informational and not investment advice.